Therapy Directory

Durvalumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Durvalumab as a study intervention. Browse Durvalumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

453

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metastatic Pancreatic Cancer
Interventions: Galunisertib, Durvalumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Scottsdale, Arizona • New York, New York • Nashville, Tennessee

Conditions: Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Interventions: Gefitinib, AZD9291, Selumetinib+Docetaxel, Tremelimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Goodyear, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 7 more

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions: Ibrutinib, MEDI4736; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Stanford, California + 8 more

Conditions: Melanoma
Interventions: Durvalumab, Dabrafenib, Trametinib; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more

Conditions: Myelodysplastic Syndrome
Interventions: MEDI4736 Evaluate MEDI4736 in MDS, VIDAZA, tremelimumab; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 12 more

Conditions: Non Small Cell Lung Cancer
Interventions: LN-145, Durvalumab; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more

Conditions: Pancreatic Cancer
Interventions: MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • The Bronx, New York

Conditions: Recurrent or Metastatic Solid Tumors
Interventions: MEDI6383, MEDI6383 and MEDI4736; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: La Jolla, California • New Haven, Connecticut • Washington D.C., District of Columbia + 4 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: MEDI4736, tremelimumab, AZD9150; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: La Jolla, California • Baltimore, Maryland • Albuquerque, New Mexico + 5 more

Conditions: Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
Interventions: Ibrutinib, Durvalumab; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more

Conditions: Solid Tumors, CTCL, Cancer
Interventions: MEDI9197, durvalumab; Drug · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Minneapolis, Minnesota + 5 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Durvalumab, Tremelimumab, SGI-110; Drug
Lead sponsor: Catherine Shu; Other
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

About this Durvalumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Durvalumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Durvalumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Durvalumab clinical trials

Filter and sort this therapy

Live official records

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

About this Durvalumab clinical trials directory page